M. Malvezzi, P. Bertuccio, F. Levi, L. Vecchia, C. Negri et al., European cancer mortality predictions for the year 2014, Annals of Oncology, vol.25, issue.8, pp.1650-1656, 2014.
DOI : 10.1093/annonc/mdu138

M. Ducreux, A. Cuhna, C. Caramella, A. Hollebecque, P. Burtin et al., Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.26, issue.suppl 5, pp.56-68, 2015.
DOI : 10.1093/annonc/mdv295

T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud et al., FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine, vol.364, issue.19, pp.1817-1842, 2011.
DOI : 10.1056/NEJMoa1011923

URL : https://hal.archives-ouvertes.fr/hal-00598658

S. Gourgou-bourgade, C. Bascoul-mollevi, F. Desseigne, M. Ychou, O. Bouche et al., Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial, Journal of Clinical Oncology, vol.31, issue.1, pp.23-32, 2013.
DOI : 10.1200/JCO.2012.44.4869

M. Diouf, T. Filleron, A. Pointet, A. Dupont-gossard, M. D. Artru et al., Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology, Quality of Life Research, vol.8, issue.1, pp.1713-1736, 2016.
DOI : 10.1586/14737167.8.2.179

D. Greenberg, C. Earle, C. Fang, A. Eldar-lissai, and P. Neumann, When is Cancer Care Cost-Effective? A Systematic Overview of Cost???Utility Analyses in Oncology, JNCI: Journal of the National Cancer Institute, vol.102, issue.2, pp.82-90, 2010.
DOI : 10.1093/jnci/djp472

G. Frederix, J. Severens, A. Hö-vels, J. Raaijmakers, and J. Schellens, The Cloudy Crystal Ball of Cost-Effectiveness Studies, Value in Health, vol.16, issue.6, pp.1100-1102, 2013.
DOI : 10.1016/j.jval.2013.06.012

M. Drummond, M. Sculpher, K. Claxton, G. Stoddart, and G. Torrance, Methods for the economic evaluation of health care programmes, 2015.

F. Kamdem, A. Nerich, V. Auber, F. Jantchou, P. Ecarnot et al., Quality assessment of economic evaluation studies in pediatric surgery: A systematic review, Journal of Pediatric Surgery, vol.50, issue.4, pp.659-87, 2015.
DOI : 10.1016/j.jpedsurg.2015.01.012

A. Guide, Choices in methods for economic evaluation. Public Health Assessment Haute Autorité de Santé, 2012.

S. Whitehead and S. Ali, Health outcomes in economic evaluation: the QALY and utilities, British Medical Bulletin, vol.96, issue.1, pp.5-21, 2010.
DOI : 10.1093/bmb/ldq033

D. Husereau, M. Drummond, S. Petrou, C. Carswell, D. Moher et al., Consolidated Health Economic Evaluation Reporting Standards (CHEERS)???Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force, Value in Health, vol.16, issue.2, pp.231-50, 2013.
DOI : 10.1016/j.jval.2013.02.002

M. Adams, N. Mccall, D. Gray, M. Orza, and T. Chalmers, Economic Analysis in Randomized Control Trials, Medical Care, vol.30, issue.3, pp.231-274, 1992.
DOI : 10.1097/00005650-199203000-00005

M. Drummond and T. Jefferson, Guidelines for authors and peer reviewers of economic submissions to the BMJ, BMJ, vol.313, issue.7052, pp.275-83, 1996.
DOI : 10.1136/bmj.313.7052.275

D. Shepard, . In, M. Gold, J. Siegel, L. Russell et al., Cost-effectiveness in Health and Medicine. By M.R. Gold, J.E Siegel, L.B. Russell, and M.C. Weinstein (eds). New York: Oxford University Press, 1996, The Journal of Mental Health Policy and Economics, vol.276, issue.2, pp.91-93, 1996.
DOI : 10.1001/jama.1996.03540160061034

S. Evers, M. Goossens, H. De-vet, M. Van-tulder, and A. Ament, Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria, Int J Technol Assess Health Care, vol.21, pp.240-245, 2005.

J. Gonzalez-perez, Developing a scoring system to quality assess economic evaluations, The European Journal of Health Economics, vol.3, issue.2, pp.131-137, 2002.
DOI : 10.1007/s10198-002-0100-2

W. Du, D. Touchette, V. Vaitkevicius, W. Peters, and A. Shields, Cost analysis of pancreatic carcinoma treatment, Cancer, vol.89, issue.9, 2000.
DOI : 10.1002/1097-0142(20001101)89:9<1917::AID-CNCR7>3.0.CO;2-L

O. Neill, C. Atoria, C. , O. Reilly, E. Lafemina et al., Costs and trends in pancreatic cancer treatment, Cancer, vol.105, issue.8 suppl, pp.5132-5141, 2012.
DOI : 10.1038/ajg.2010.32

D. Abbott, R. Merkow, S. Cantor, J. Fleming, G. Varadhachary et al., Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement, Annals of Surgical Oncology, vol.29, issue.12, pp.3659-67, 2012.
DOI : 10.1200/JCO.2010.32.1075

D. Abbott, C. Tzeng, R. Merkow, S. Cantor, G. Chang et al., The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma, Annals of Surgical Oncology, vol.204, issue.S3, pp.500-508, 2013.
DOI : 10.1016/j.jamcollsurg.2006.12.011

M. Aristides, M. Lees, N. Botwood, J. Mckendrick, D. Stephenson et al., Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK, The European Journal of Health Economics, vol.4, issue.3, pp.216-237, 2003.
DOI : 10.1007/s10198-003-0173-6

C. Attard, S. Brown, K. Alloul, and M. Moore, Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer, Current Oncology, vol.21, issue.1, pp.41-51, 2014.
DOI : 10.3747/co.21.1327

J. Zhou, R. Zhao, F. Wen, P. Zhang, R. Tang et al., Costeffectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study, Med Oncol, p.32, 2015.

A. Carrato, P. García, R. Ló-pez, T. Macarulla, F. Rivera et al., -paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study, Expert Review of Pharmacoeconomics & Outcomes Research, vol.16, issue.4, pp.579-89, 2015.
DOI : 10.1586/erp.13.18

URL : https://hal.archives-ouvertes.fr/halshs-00741378

M. Gharaibeh, A. Mcbride, J. Bootman, and I. Abraham, Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer, British Journal of Cancer, vol.15, issue.8, pp.1301-1306, 2015.
DOI : 10.1200/JCO.2011.36.5742

V. Tam, Y. Ko, N. Mittmann, M. Cheung, K. Kumar et al., Cost-effectiveness of systemic therapies for metastatic pancreatic cancer, Curr Oncol, vol.201320

D. Ansari, B. Tingstedt, and R. Andersson, Pancreatic cancer ??? cost for overtreatment with gemcitabine, Acta Oncologica, vol.30, issue.6, pp.1146-51, 2013.
DOI : 10.1158/1078-0432.CCR-09-1555

C. Wang, H. Wu, J. Xiong, F. Zhou, J. Tao et al., Pancreaticoduodenectomy with Vascular Resection for Local Advanced Pancreatic Head Cancer: A Single Center Retrospective Study, Journal of Gastrointestinal Surgery, vol.21, issue.12, pp.2183-90, 2008.
DOI : 10.1136/gut.2006.113068

M. Mortenson, H. Ho, and R. Bold, An analysis of cost and clinical outcome in palliation for advanced pancreatic cancer, The American Journal of Surgery, vol.190, issue.3, pp.406-417, 2005.
DOI : 10.1016/j.amjsurg.2005.03.014

M. Krzyzanowska, C. Earle, K. Kuntz, and J. Weeks, Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer, International Journal of Radiation Oncology*Biology*Physics, vol.67, issue.1, pp.211-219, 2007.
DOI : 10.1016/j.ijrobp.2006.07.1390

J. Murphy, D. Chang, J. Abelson, M. Daly, H. Yeung et al., Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer, Cancer, vol.82, issue.3 suppl, pp.1119-1148, 2012.
DOI : 10.1054/bjoc.2000.1142

W. Tierney, A. Fendrick, R. Hirth, and J. Scheiman, The clinical and economic impact of alternative staging strategies for adenocarcinoma of the pancreas, The American Journal of Gastroenterology, vol.45, issue.7, pp.1708-1721, 2000.
DOI : 10.1146/annurev.med.46.1.361

G. Harewood and M. Wiersema, A cost analysis of endoscopic ultrasound in the evaluation of pancreatic head adenocarcinoma, The American Journal of Gastroenterology, vol.117, issue.9
DOI : 10.1016/S0002-9610(97)00132-3

P. Mcmahon, E. Halpern, F. Castillo, C. Clark, J. Gazelle et al., Pancreatic cancer: cost-effectiveness of imaging technologies for assessing resectability A costminimization analysis of alternative strategies in diagnosing pancreatic cancer, Radiology Am J Gastroenterol, vol.22199, pp.2223-2257, 2001.

S. Heinrich, G. Goerres, M. Schäfer, M. Sagmeister, P. Bauerfeind et al., Positron Emission Tomography/Computed Tomography Influences on the Management of Resectable Pancreatic Cancer and Its Cost-Effectiveness, Annals of Surgery, vol.242, issue.2, pp.235-278, 2005.
DOI : 10.1097/01.sla.0000172095.97787.84

C. Enestvedt, S. Mayo, B. Diggs, M. Mori, D. Austin et al., Diagnostic Laparoscopy for Patients with Potentially Resectable Pancreatic Adenocarcinoma: Is It Cost-Effective in the Current Era?, Journal of Gastrointestinal Surgery, vol.153, issue.9, pp.1177-84, 2008.
DOI : 10.1001/archpedi.153.9.965

E. Tapper, B. Kalb, D. Martin, D. Kooby, N. Adsay et al., Staging laparoscopy for proximal pancreatic cancer in a magnetic resonance imaging-driven practice: what's it worth?, HPB, vol.13, issue.10, pp.732-739, 2011.
DOI : 10.1111/j.1477-2574.2011.00366.x

T. Jayakrishnan, H. Nadeem, R. Groeschl, B. George, J. Thomas et al., Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument, HPB, vol.17, issue.2, pp.131-140, 2015.
DOI : 10.1111/hpb.12325

S. Rulyak, M. Kimmey, D. Veenstra, and T. Brentnall, Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds, Gastrointestinal Endoscopy, vol.57, issue.1, pp.23-32, 2003.
DOI : 10.1067/mge.2003.28

A. Latchford, W. Greenhalf, L. Vitone, J. Neoptolemos, G. Lancaster et al., Peutz???Jeghers syndrome and screening for pancreatic cancer, British Journal of Surgery, vol.15, issue.12, pp.1446-55, 2006.
DOI : 10.4161/cbt.183

J. Rubenstein, J. Scheiman, and M. Anderson, A Clinical and Economic Evaluation of Endoscopic Ultrasound for Patients at Risk for Familial Pancreatic Adenocarcinoma, Pancreatology, vol.7, issue.5-6, pp.514-539, 2007.
DOI : 10.1159/000108969

O. Ghatnekar, R. Andersson, M. Svensson, U. Persson, U. Ringdahl et al., Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature, International Journal of Cancer, vol.9, issue.10, pp.2392-2399, 2013.
DOI : 10.1159/000210262

M. Arguedas, G. Heudebert, A. Stinnett, and C. Wilcox, Biliary stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis, The American Journal of Gastroenterology, vol.200, issue.4, pp.898-904, 2002.
DOI : 10.1111/j.1572-0241.2001.03594.x

V. Chen, M. Arguedas, and T. Baron, Expandable Metal Biliary Stents Before Pancreaticoduodenectomy for Pancreatic Cancer: A Monte-Carlo Decision Analysis, Clinical Gastroenterology and Hepatology, vol.3, issue.12, pp.1229-1266, 2005.
DOI : 10.1016/S1542-3565(05)00886-4

M. Kahaleh, A. Brock, M. Conaway, V. Shami, J. Dumonceau et al., Covered self-expandable metal stents in pancreatic malignancy regardless of resectability: a new concept validated by a decision analysis, Endoscopy, vol.39, issue.04, pp.319-343, 2007.
DOI : 10.1055/s-2007-966263

E. Witkowski, J. Smith, E. Ragulin-coyne, S. Ng, S. Shah et al., Is It Worth Looking? Abdominal Imaging After Pancreatic Cancer Resection: a National Study, Journal of Gastrointestinal Surgery, vol.116, issue.7, pp.121-129, 2012.
DOI : 10.1002/cncr.24918

C. Tzeng, D. Abbott, S. Cantor, J. Fleming, J. Lee et al., Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis, Annals of Surgical Oncology, vol.3, issue.7, pp.2197-203, 2013.
DOI : 10.1245/ASO.2004.03.040

B. Shea, J. Grimshaw, G. Wells, M. Boers, N. Andersson et al., Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews, BMC Medical Research Methodology, vol.333, issue.4, p.10, 2007.
DOI : 10.1136/bmj.333.7568.597

B. Shea, C. Hamel, G. Wells, L. Bouter, E. Kristjansson et al., AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews, Journal of Clinical Epidemiology, vol.62, issue.10, pp.1013-1033, 2009.
DOI : 10.1016/j.jclinepi.2008.10.009

M. Gharaibeh, J. Bootman, A. Mcbride, J. Martin, and I. Abraham, Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review, PharmacoEconomics, vol.12, issue.1, pp.83-95, 2017.
DOI : JOP.2015.005876

S. Gerkens, R. Crott, I. Cleemput, J. Thissen, M. Closon et al., Comparison of three instruments assessing the quality of economic evaluations: A practical exercise on economic evaluations of the surgical treatment of obesity, International Journal of Technology Assessment in Health Care, vol.29, issue.03, pp.318-343, 2008.
DOI : 10.1037/0033-2909.86.2.420

G. Frederix, J. Van-hasselt, J. Schellens, A. Hö-vels, J. Raaijmakers et al., The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance, PharmacoEconomics, vol.121, issue.2, pp.47-61, 2014.
DOI : 10.1007/s10549-010-0870-7

A. Briggs, M. Weinstein, E. Fenwick, J. Karnon, M. Sculpher et al., Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6, Value in Health, vol.15, issue.6, pp.835-877, 2012.
DOI : 10.1016/j.jval.2012.04.014

P. Neumann, P. Stone, R. Chapman, E. Sandberg, and C. Bell, The Quality of Reporting in Published Cost-Utility Analyses, 1976???1997, Annals of Internal Medicine, vol.132, issue.12, pp.964-72, 2000.
DOI : 10.7326/0003-4819-132-12-200006200-00007

P. Aguiar, T. Lima, and S. Storpirtis, Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?, Journal of Clinical Pharmacy and Therapeutics, vol.3, issue.2, pp.189-97, 2016.
DOI : 10.1007/s11912-001-0027-2

V. Nerich, S. Saing, E. Gamper, G. Kemmler, F. Daval et al., Cost???utility analyses of drug therapies in breast cancer: a systematic review, Breast Cancer Research and Treatment, vol.26, issue.Suppl 5 Develop, pp.407-431, 2016.
DOI : 10.2165/00019053-200826050-00005